Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"
DID YOU KNOW?
Glycerin is among the most popular ingredients in beauty products, behind water and fragrance.1 With a 50+ year history of use, glycerin is a deceptively simple molecule classified as a powerful humectant that is anything but basic.
Glycerin is recognized by the U.S. Food & Drug Administration (FDA) as an over-the-counter skin protectant when used between 20-45%.2
… 
This month’s Patient Buzz includes articles that sought to predict the top skincare trends for 2023.
Are you in the know about the latest trends? Peruse this list of dermatology articles in the consumer press:
Allure: Cardi B has butt injections removed
Allure: Neuromodulator guide
Allure: Skincare trends for 2023
BestLife/Yahoo! Life: Skincare after 50
CNET: Good skin … 
As a former vitiligo clinical trials research fellow, I have attended more than my fair share of presentations on vitiligo. Yet, I am amazed at how each additional lecture continues to teach me new and exciting concepts and treatment options for vitiligo. Dr. Seemal Desai’s lecture at the 2022 Skin of Color Update Conference was no exception to this rule.
During the SOCU Conference held in Ne … 
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat rheumatoid arthritis and psoriatic arthritis, but was recently FDA approved i …